Article

Contact lens approved for use as bandage lens

A contact lens (Acuvue Oasis, Vistakon) has received FDA approval for therapeutic use as a bandage lens for certain acute and chronic ocular conditions.

Jacksonville, FL-A contact lens (Acuvue Oasis, Vistakon) has received FDA approval for therapeutic use as a bandage lens for certain acute and chronic ocular conditions.

"The wettability, smoothness, flexibility, high [level of] oxygen transmissibility, comfort, and Class I [ultraviolet light]-blocking properties of [the lens] make it an excellent choice for therapeutic use as a bandage lens for a range of conditions," said Sheila Hickson-Curran, director, medical affairs, Vistakon.

William B. Trattler, MD, a cornea specialist at the Center for Excellence in Eyecare, Miami, and a volunteer assistant professor at Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, said, "Under certain conditions, the use of a silicone hydrogel lens like [this lens] can help protect the cornea from exposure or repeated irritation often caused by rubbing during the wound-healing process and [can] assist in pain relief. For my patients, I have also found that [this lens] works wonderfully as a bandage contact lens for laser vision correction, as it reduces discomfort."

The recent FDA approval includes these uses:

The lens can be worn continuously for up to 6 nights and 7 days when used as a therapeutic lens. It also is indicated for daily wear vision correction and may be worn consecutively for up to 6 nights and 7 days of extended wear as recommended by an eye-care professional.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.